Francis H Bateman
(2027-2030) Ph.D. Candidate, Pharmaceutical Sciences, Clinical Pharmacology Laboratory, Clinical Center, National Institutes of Health
(2025-2027) Ph.D. Student, Pharmaceutical Sciences, Eshelman School of Pharmacy, Division of Chemical Biology and Medicinal Chemistry & Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill
Scientist with a foundation in clinical and quantitative pharmacology, pharmacometrics, systems biology and development of AI and ML models interested in answering complex questions about drug discovery and development.
My background spans analytical chemistry, clinical pharmacology, and computational modeling. At the NIH's Laboratory of Clinical Pharmacology and subsequently UNC LCCC’s Advanced Translational Pharmacology Laboratory, I developed bioanalytical assays for novel therapeutics using LC/MS/MS and ELISA, then applied tools like R, Julia, NONMEM, and Phoenix to build compartmental and population pharmacokinetic models to simulate drug behavior across large, diverse populations.
In late 2026, my PhD advisor in the ATPAC lab, Dr. William Zamboni, left for the University of Pittsburgh. I stayed in the UNC ESoP degree program, however my dissertation work was completed at the National Institutes of Health's Clinical Pharmacology laboratory with advisor Dr. William Douglas Figg Sr. In this position I study the application of principles of clinical pharmacology, pharmacometrics, and pharmacogenomics to the disposition and effects associated with chemotherapies. I also contribute through pharmacometric analyses to multiple Phase I/II clinical trials, primarily oncology.
Following the completion of my Ph.D. I hope to pursue medical education, deepening my understanding of cancer and learning how to treat patients human to human. It is my long term goal to stay in academic medicine and lead an experimental therapeutics/phase I/II unit at a cancer center.
My background spans analytical chemistry, clinical pharmacology, and computational modeling. At the NIH's Laboratory of Clinical Pharmacology and subsequently UNC LCCC’s Advanced Translational Pharmacology Laboratory, I developed bioanalytical assays for novel therapeutics using LC/MS/MS and ELISA, then applied tools like R, Julia, NONMEM, and Phoenix to build compartmental and population pharmacokinetic models to simulate drug behavior across large, diverse populations.
In late 2026, my PhD advisor in the ATPAC lab, Dr. William Zamboni, left for the University of Pittsburgh. I stayed in the UNC ESoP degree program, however my dissertation work was completed at the National Institutes of Health's Clinical Pharmacology laboratory with advisor Dr. William Douglas Figg Sr. In this position I study the application of principles of clinical pharmacology, pharmacometrics, and pharmacogenomics to the disposition and effects associated with chemotherapies. I also contribute through pharmacometric analyses to multiple Phase I/II clinical trials, primarily oncology.
Following the completion of my Ph.D. I hope to pursue medical education, deepening my understanding of cancer and learning how to treat patients human to human. It is my long term goal to stay in academic medicine and lead an experimental therapeutics/phase I/II unit at a cancer center.